All In Biotech

Drug Trial Radar · NCT05935748

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination With Palbociclib (Doublet) and With Palbociclib and Sasanlimab (Triplet) in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

18

Actual

Start

Jul 28, 2023

Primary completion

Jun 30, 2025

Study completion Sep 4, 2025

Sponsor

Lead sponsor
NiKang Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Pfizer
First posted
Jul 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the Lead-in phase of the study is to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy. The goal of the Expansion phase of the study is to evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy.

Conditions

  • ccRCC
  • Clear Cell Renal Cell Carcinoma
  • Kidney Cancer
  • Kidney Neoplasms
  • Renal Cancer
  • Renal Neoplasms
  • Recurrent Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma
  • Refractory Renal Cell Carcinoma
  • Advanced Renal Cell Carcinoma
  • Carcinoma
  • Neoplasms
  • Carcinoma, Renal Cell
  • Neoplasms, Glandular and Epithelial
  • Neoplasm by Histology
  • Adenocarcinoma
  • Urologic Neoplasms
  • Urogenital Neoplasms
  • Neoplasms by Site
  • Kidney Diseases
  • Urologic Diseases

Interventions

  • NKT2152Drug

    Oral HIF2a inhibitor

  • palbociclibDrug

    a cyclin-dependent kinases (CDK) 4 and 6 inhibitor

  • sasanlimabOther

    an immunoglobulin G4 (IgG4) monoclonal antibody that blocks PD-1; a solution for injection for subcutaneous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicity (DLT) Events During the DLT Monitoring Period (First 28 Days of Dosing) in the Lead-in PhaseTime frame: 28 days
  2. Objective Response Rate (ORR) Determined by the InvestigatorTime frame: 1 years

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Diego

    La Jolla, California

  • Northwestern University - Feinberg School of Medicine

    Chicago, Illinois

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan-Rogel Cancer Center

    Ann Arbor, Michigan

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • UT Southwestern Medical Center

    Dallas, Texas

  • University of Virginia Health System

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.